[Identification of gastric cancer patients by serum protein profiling]
>>J Proteome Res. 2004 Nov-Dec;3(6):1261-6.
Identification of gastric cancer patients by serum protein profiling.
Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, Malfertheiner P, Rocken C.
Departments of Gastroenterology, Hepatology and Infectious Diseases, Pathology, and General Surgery, Otto-von-Guericke University, D-39120 Magdeburg, Germany and Europroteome AG, D-16761 Berlin-Hennigsdorf, Germany.
Using surface-enhanced laser desorption ionization mass spectrometry (SELDI/TOF-MS) and ProteinChip technology, coupled with a pattern-matching algorithm and serum samples, we screened for protein patterns to differentiate gastric cancer patients from noncancer patients. A classifier ensemble, consisting of 50 decision trees, correctly classified all gastric cancers and all controls of a training set (100% sensitivity and 100% specificity). Eight of 9 stage I gastric cancers (88.9% sensitivity for stage I) were correctly classified. In addition, 28 sera from gastric cancer patients taken in different hospitals were correctly classified (100% sensitivity). Furthermore, all 11 control sera obtained from patients without gastric cancer (100% specificity) were classified correctly and 29 of 30 healthy blood-donors were classified as noncancerous. ProteinChip technology in conjunction with bioinformatics allows the highly sensitive and specific recognition of gastric cancer patients.<<
Nice, but room for improvement at Stage I, where it matters.
Cheers, Tuck |
